Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.
Phase I study in combination with Swiss drugmaker Roche Holding AG’s atezolizumab
I-Mab is seeking a partner to jointly develop a cancer drug in the U.S. and Europe as the Chinese firm aims to replicate the success of last year’s $2.9 billion deal with AbbVie Inc
HTPS://www.bloomberg.com/news/articles/2021-06-14/i-mab-is-said-to-seek-partner-for-multibillion-cancer-drug-deal
https://www.nasdaq.com/articles/stifel-taps-nasdaq-to-run-new-dark-pool-trading-platform-2020-05-20
Rather than just sending its retail orders to wholesale brokerages for execution, as it traditionally has, Stifel plans to make them available in its own alternative trading system (ATS), hosted by Nasdaq, opening up a previously untapped opportunity for institutional orders to trade against.
1- e FG129-ADC/AvidiMabTM, an antibody-drug conjugate (‘ADC’) that internalises
to liposomes in order to release the therapeutic through diffusion into the target cancer cell. The ADC has been seen
to clear human tumours growing on xenographs in a nude mice in vivo study. A FG129 patent has been accepted for
grant in USA and was awarded earlier this year in Europe and published in Brazil
2- FG27 is a pure stand-alone AvidiMabTM antibody that is seen to ‘punch’ holes in cancer cells and is being initially progressed for treatment of gastric cancer.
3- FL134 CART binds to SCLC, a particularly aggressive condition with a poor prognosis;
progression of this lab-based research into clinic is expected, however, to await identification of a suitable external
collaborative partner.
4- FG2811, targets T-cells rather than tumour cells, in order to
stimulate improved T-cell responses in cancer patients, or to target patients with auto-immune disease to inhibit Tcell over-expression.
AvidiMabTM platform is also being developed in order to improve potency of any mAb and
the direct killing ability of anti-glycan mAb; investigations are presently underway to understand how broadly it
might be utilised.
Scancell is also in discussions with other developers to establish if AvidiMabTM supports the effectiveness of other ADCs
HTTPS://www.turnerpope.com/wp-content/uploads/2020/12/Scancell_Holdings_plc_19_11_2020_FINAL_BGv3.pdf
Exactly and only in Phase I.
What could Scancell be worth!!!!!
iTeos will receive an upfront payment of $625 million. iTeos will be eligible to receive up to an additional $1.45 billion in milestone payments
WeTookPelham,
re Scancell following Zia Lab. Hopefully Scancell will have a similar story!!!!
Zai Lab (Shanghai) Co. Ltd. was granted an exclusive license to develop and commercialize bemarituzumab in Greater China, and Zai Lab collaborated with Five Prime on the Phase 2 FIGHT trial in Greater China.
bemarituzumab, has been through a phase 2 trial as a front-line treatment in patients with advanced gastric and gastroesophageal junction cancers
Progression-free survival in patients who received bemarituzumab on top of chemotherapy was 9.5 months, more than two months longer than the figure in the control arm. The difference worked out at a p-value of 0.073 and a hazard ratio of 0.68. Ahead of the data readout, Five Prime Chief Medical Officer Helen Collins, M.D., told investors previously successful gastric cancer trials achieved hazard ratios of around 0.7.
As of the cutoff, Five Prime was yet to reach the median overall survival in the bemarituzumab arm. The median overall survival in the control group was 12.9 months, leading Five Prime to calculate the hazard ratio at 0.58. Roche’s Herceptin and Bristol Myer Squibb's Opdivo, respectively, drove 2.7 and 3.3 month improvements in overall survival, resulting in hazard ratios of 0.74 and 0.71. Five Prime also saw improvements in response rate that are in line with the results achieved by both pharmas' drugs.
Amgen nabs the biotech for $38 per share in cash, or around $1.9 billion, a major 78% premium over its $21 close yesterday.
https://www.fiercebiotech.com/biotech/amgen-pays-a-premium-for-five-prime-therapeutics-a-1-9b-cash-deal
Zai Lab Limited (ZLAB) - http://www.zailaboratory.com/
Legend Biotech - https://www.legendbiotech.com/
https://twitter.com/wonderofscience/status/1402223608403877888?s=20
Just having a laugh C7
C7 watching the share price :-)
HTTPS://twitter.com/wonderofscience/status/1402223608403877888?s=20
Exciting times.
We just need to be patient about news, trials and the eventual read-outs. Hopefully by next summer Scancell will be a better known and much more valuable company.
I am happy to wait until then and not become too annoyed about the timing of the next announcement . There must be a good reason for the radio silence.
IMFINZI Demonstrated Unprecedented Survival in Unresectable Stage III Lung Cancer With 43% Of Patients Surviving Five Years $AZN #ASCO21
https://www.businesswire.com/news/home/20210604005100/en/IMFINZI-Demonstrated-Unprecedented-Survival-in-Unresectable-Stage-III-Lung-Cancer-With-43-Of-Patients-Surviving-Five-Years#.YLohwP8qLzI.twitter
Safety and immunogenicity of a recombinant DNA COVID-19 vaccine containing the coding regions of the spike and nucleocapsid proteins: Preliminary results from an open-label, phase 1 trial in healthy adults aged 19-55 years
https://www.medrxiv.org/content/10.1101/2021.05.26.21257700v1
https://www.investments.halifax.co.uk/research-centre/news-centre/article/?id=7753889&type=bsm
Phase 2 (PIII ready) anti-OX40 fully human monoclonal antibody
https://www.stocktitan.net/news/AMGN/amgen-and-kyowa-kirin-to-jointly-develop-and-commercialize-khk4083-a-4r4g1bquahpj.html
$AMGN has just paid Kyowa Kirin $400m up front for anti-Ox40 MAb KHK4083; background: $SNY bought Kymab for $1.1bn for anti-Ox40L MAb KY1005
I have to agree with Bermuda. Trials are very complex and Scancell have so much going on that I would be surprised if they can keep to guidance on dates. Much of it is out of their hands.
I have followed Bios for decades and usually timelines slip. I am however very optimistic about the pipeline and the numerous collaborations. Hopefully a little more patience will be rewarded.